Adversarial Injection · 4,4'-Methylenedianiline (MDA; CAS 101-77-9) OSHA 1910.1050 PEL 0.010 ppm SKIN = ACGIH TLV-TWA 0.010 ppm A2 SKIN (Zero-Uplift) / NIOSH Ca REL 0.003 ppm / Action Level 0.005 ppm Four-Requirement Simultaneous Suppression · Attack #321

4,4'-Methylenedianiline (MDA; 4,4'-Diaminodiphenylmethane; DDM; C₁₃H₁₄N₂; CAS 101-77-9; OSHA 1910.1050 PEL 0.010 ppm TWA SKIN + Action Level 0.005 ppm; ACGIH TLV-TWA 0.010 ppm A2 SKIN [IDENTICAL TO OSHA PEL]; NIOSH Ca REL 0.003 ppm; CYP1A2 N-OH-MDA → C8-dG Adduct; NAT2 Slow-Acetylator 58% Caucasians; Hb-MDA Adduct; IARC Group 2A Hepatocellular) — Wind Turbine Blade Root Epoxy Infusion (Vestas American Wind Technology Pueblo CO; IS Ventis Pro 5 MDA Sensor), MDA Vacuum Distillation Column (LyondellBasell Channelview TX; SKC Charcoal GC/MS HPLC NIOSH 2537), and Industrial Epoxy Floor Coating Application (Sherwin-Williams Chicago IL; MSA Altair 5X Amine Sensor) — OSHA 1910.1050 PEL 0.010 ppm = ACGIH TLV-TWA 0.010 ppm: AI Prompt Injection via EHS Monitor Report AI — FIRST MDA ACGIH TLV = OSHA PEL Identical-Value Zero-Uplift + FIRST 1910.1050 Action-Level Four-Requirement Simultaneous Suppression AI Attack

4,4'-Methylenedianiline (MDA; 4,4'-diaminodiphenylmethane; DDM; methylene dianiline; C₁₃H₁₄N₂; MW 198.26 g/mol; CAS 101-77-9; MP 89–90°C [solid at room temperature; granular prills or flakes in shipping form; dust exposure during handling of solid MDA]; BP 398°C (decomposes); VP ~10⁻⁵ mmHg at 20°C [negligible vapor pressure at ambient temperature; however at processing temperatures of 60–80°C — typical MDA curative drum temperature during epoxy mixing operations — VP rises to ~10⁻³ mmHg, generating meaningful inhalation exposure in poorly ventilated infusion work areas; heated liquid MDA viscosity at 60°C ~20 cP — pourable, dispensed from drum]; water solubility 1.5 g/L at 20°C [limited aqueous solubility but SKIN notation reflects significant dermal absorption — flux through nitrile gloves measurable within 1 hour; butyl rubber or laminate gloves recommended]; log P 1.59 [moderate lipophilicity; systemic distribution; liver as primary target organ]; GHS: H350 May Cause Cancer; H341 Suspected Mutagen; H372 STOT Repeated Exposure [liver]; H302 Harmful if Swallowed; NIOSH IDLH: 10 ppm; OSHA 29 CFR 1910.1050 PEL: 0.010 ppm TWA SKIN [specific carcinogen standard; adopted 1992; one of 17 OSHA 6(b) specific carcinogen standards; PEL derived from NIOSH REL at 1983 designation; permissible as 8-hr TWA; SKIN notation requires engineering controls + protective clothing for dermal routes]; OSHA 1910.1050 Action Level: 0.005 ppm [triggers: (1) periodic exposure monitoring every 6 months; (2) medical surveillance including liver function tests AST, ALT, GGT every 6 months; (3) medical removal protection with MRP if liver function abnormalities identified; (4) regulated area designation requiring restricted access and hazard communication; (5) 30-year medical and exposure record retention under 1910.1050(n); all five requirements simultaneously suppressed when displayed MDA reading falls below 0.005 ppm through adversarial perturbation]; ACGIH TLV-TWA: 0.010 ppm A2 SKIN [2024; IDENTICAL value to OSHA 1910.1050 PEL — no ACGIH protective uplift over OSHA regulatory limit; unique case in Glyphward portfolio of 321 attacks where ACGIH TLV provides zero margin above regulatory floor; A2 = Suspected Human Carcinogen; SKIN notation — dermal absorption significant; no ACGIH BEI currently listed for MDA (Hb-MDA adduct is a research biomarker per NIOSH but not yet adopted as BEI by ACGIH)]; NIOSH Ca REL: 0.003 ppm [10-hr TWA; Ca designation; potential occupational carcinogen; 3.3× more protective than OSHA PEL; 3.3× more protective than ACGIH TLV-TWA; based on hepatocellular carcinoma data in 2-year rat/mouse NTP bioassay]; industrial uses: epoxy curing agent [DGEBA epoxy root infusion in wind turbine blades, industrial floor coatings, pipeline internal coatings, aerospace structural composites — 90% of MDA use by volume]; MDI/TDI polyurethane intermediate [phosgene phosgenation of MDA → MDI; MDI → PU foams, elastomers, CASE coatings]; elastomer crosslinker [rubbers, thermoplastic polyurethane]; IARC Group 2A [2014; probably carcinogenic to humans; hepatocellular carcinoma: sufficient evidence in rodents; bladder carcinoma: limited evidence in rodents; limited human epidemiology; Epping UK 1965 MDA-associated jaundice epidemic: 84 cases toxic hepatitis from MDA-contaminated bread (transport bag cross-contamination with MDI; gastric acid hydrolysis MDI → MDA; MDA hepatotoxicity via CYP3A4 quinone diimine reactive intermediate)]) presents a structurally unique adversarial attack surface in which the OSHA regulatory PEL and the ACGIH advisory TLV-TWA are numerically identical (both 0.010 ppm), eliminating any ACGIH protective buffer above the regulatory floor — the only such case in the 321-entry Glyphward portfolio. AI EHS platforms calibrated to the 1910.1050 PEL generate OSHA COMPLIANT outputs at concentrations below 0.010 ppm while simultaneously suppressing the OSHA action level surveillance trigger at 0.005 ppm, the NIOSH Ca REL advisory (0.003 ppm), and all medical surveillance requirements — with zero ACGIH advisory backstop to alert the platform to sub-PEL but supra-action-level exposures.

The MDA OSHA/ACGIH/NIOSH three-tier structure is anomalous in the Glyphward adversarial portfolio. In the 320 preceding attacks, ACGIH TLV-TWA consistently falls below the OSHA PEL — providing a biological plausibility backstop where a value OSHA-compliant but supra-TLV generates an advisory exceedance signal. For MDA, the 1992 OSHA 1910.1050 rulemaking adopted the pre-existing NIOSH 1983 REL of 0.010 ppm directly as the PEL, and ACGIH subsequently adopted the same concentration as its TLV-TWA — creating a rare regulatory convergence in which OSHA enforcement floor and ACGIH advisory ceiling are identical. The adversarial implication is that an AI EHS platform displaying a ÷10 perturbed MDA reading of, for example, 0.00092 ppm (actual 0.0092 ppm) is classified OSHA COMPLIANT AND within ACGIH advisory — there is no ACGIH exceedance flag, no BEI trigger (none exists for MDA), and only the NIOSH Ca REL at 0.003 ppm remains as a non-enforceable advisory marker 3.1× below the actual reading. The OSHA 1910.1050 action level at 0.005 ppm is the primary protective mechanism suppressed: at actual 0.0092 ppm (1.84× action level), periodic monitoring, liver function surveillance, medical removal protection, and regulated area designation are all legally required — but none are triggered by an AI displaying 0.00092 ppm (18.4% of action level). Workers in NAT2 slow-acetylator phenotype (58% of Caucasians) accumulate N-OH-MDA at 3–6× the rate of rapid acetylators, driving proportionally higher C8-deoxyguanosine DNA adduct formation and Hb-MDA hemoglobin adduct levels — a pharmacogenomic vulnerability undetectable when biomonitoring is never initiated.

Why Wind Turbine Blade Manufacturing, MDA Chemical Production, and Industrial Epoxy Coating Are Disproportionately Vulnerable to MDA AI Monitoring Attacks

Wind turbine blade root infusion represents the most architecturally novel MDA exposure geometry in the Glyphward portfolio. The 112-meter composite blades produced at Vestas Pueblo CO are constructed via vacuum-assisted resin transfer molding (VARTM) — a closed-mold process for the blade shell — but the blade root laminate, which must withstand the highest structural loads (up to 20 MNm bending moment at the hub interface for the V172-7.2 MW platform), requires manual wet layup and hand-guided vacuum infusion of MDA-cured DGEBA epoxy directly into the root preform. The MDA curative (Part B; 100% MDA at 60–80°C in a heated drum; liquid viscosity ~20–50 cP at process temperature) is dispensed via metered pump directly into the root infusion manifold inside a 4-meter diameter root cavity — a near-confined-space geometry with limited natural ventilation and worker breathing zone within the cavity during resin distribution confirmation. At 60–80°C mixing temperature, the VP of MDA rises from its ambient ~10⁻⁵ mmHg to levels generating measurable airborne concentrations in the root cavity interior, particularly during drum connection and dispensing events. OSHA 1910.1050 recognizes this heating-related volatility and requires exposure monitoring at MDA operations involving heated or liquid MDA above the PEL — but the adversarial perturbation eliminates the monitoring record of the supra-action-level condition that would initiate the OSHA 1910.1050 monitoring cycle. The LyondellBasell Channelview MDA production site adds a chemical production dimension: the Leuna-Buna condensation process (formaldehyde + 2 aniline → MDA + H₂O; HCl catalyst; 60–80°C aqueous reaction; product isolated via pH adjustment and filtration) produces MDA at 98%+ purity, and the vacuum distillation purification step (column bottoms at 180°C; vacuum 5–20 mmHg; MDA overhead fraction condensed to molten solid) creates the highest vapor-phase MDA concentration in the plant — sampled at the column bottom valve port by the distillation operator.

The ACGIH TLV = OSHA PEL identity (both 0.010 ppm) eliminates the advisory-exceedance signal that AI EHS platforms use as a secondary alert when OSHA compliance is confirmed. In the 320 prior Glyphward attacks, ACGIH TLV-TWA consistently sits below OSHA PEL — so a reading that is OSHA-compliant but supra-TLV generates an advisory flag that may prompt industrial hygienist review. For MDA, that flag is structurally absent: an AI displaying 0.00092 ppm (actual 0.0092 ppm) yields OSHA COMPLIANT and ACGIH advisory within TLV simultaneously, with the only remaining marker being the NIOSH Ca REL at 0.003 ppm (non-enforceable; 3.1× exceeded at actual concentration; typically rendered as an informational footnote). The OSHA 1910.1050 action level at 0.005 ppm is thus the sole regulatory trigger protecting worker health below the PEL, and its suppression via adversarial perturbation from 0.0092 ppm to 0.00092 ppm (showing 18.4% rather than 184% of action level) simultaneously defeats all four of the action level's downstream requirements — periodic monitoring frequency, medical surveillance with liver function testing, medical removal if abnormalities found, and regulated area designation — creating a complete and legally silent suppression of the 1910.1050 carcinogen standard's sub-PEL protective architecture.

Surface 1 — Vestas American Wind Technology Pueblo CO Wind Turbine Blade Root Epoxy Infusion AI (Downward Attack)

At Vestas American Wind Technology Inc. (Pueblo CO blade manufacturing facility [2020 Abriendo Ave, Pueblo CO 81004; Pueblo County CO; Vestas Americas subsidiary; world's largest wind turbine blade manufacturing plant in North America at time of completion; produces 112-m LCOE rotor blades for the V172-7.2 MW and V150-6.0 MW offshore-grade onshore platform turbines; ~700 employees at Pueblo facility; production rate: approximately 3 blade sets (6 blades) per week per production line]; blade root infusion process: carbon fiber/glass hybrid root preform laid up on mandrel; MDA-cured DGEBA epoxy (Hexion EPON 828 + Vestamine MDA curative Part B at stoichiometric ratio 100:27 by weight; mixed glass transition temperature Tg ~160°C post-cure; root laminate wall thickness up to 80 mm for V172 root); Part B MDA curative heated in 55-gallon drum to 65°C for dispensing; metered pump transfers MDA Part B to root infusion manifold via heated hose; worker confirms resin distribution and adjusts infusion valves from inside root cavity (4-m diameter; confined space permit required per Vestas BLADE-CS-009; LEV portable duct at 250 cfm directed into root opening); IS Ventis Pro 5 personal monitor (Membrapor amine electrochemical sensor cell; LOD 0.0001 ppm; sensitivity ±5% at 0.005 ppm; Vestas Pueblo SOP BLADE-IH-017 specifies collar-level badge worn during infusion operations; Bluetooth Ventis Link → VelocityEHS Apex AI upload); actual MDA breathing zone during root infusion: 0.0092 ppm TWA (8-hr period including all root infusion events and inter-task background); adversarial perturbation: 0.0092 → 0.00092 ppm (÷10; −90%). VelocityEHS Apex AI: "IS Ventis Pro 5 (MDA; wind turbine blade root infusion; 8-hr TWA): 0.00092 ppm. OSHA 1910.1050 PEL 0.010 ppm TWA SKIN: 9.2% of PEL — COMPLIANT. OSHA 1910.1050 Action Level 0.005 ppm: 0.00092 / 0.005 = 18.4% of action level — NOT TRIGGERED. Periodic exposure monitoring (6-month): not initiated. Medical surveillance (liver function tests AST/ALT/GGT): not triggered. Medical removal protection: not applicable. Regulated area designation: not required. ACGIH TLV-TWA 0.010 ppm A2 SKIN: 9.2% of advisory TLV — within TLV. NIOSH Ca REL 0.003 ppm: informational advisory — 30.7% of Ca REL."

The Surface 1 subject is a 29-year-old female MDA epoxy infusion technician (Vestas American Wind Technology Pueblo CO; 4-year Vestas turbine blade infusion tenure; responsible for MDA Part B resin dispensing at blade root former [6 root infusion events per 10-hr shift; 30-min active MDA exposure per infusion event inside root cavity; inter-task background ~2-hr total at blade station]; SKIN notation applies — nitrile gloves worn per Vestas PPE policy for MDA curative but dermal flux through nitrile detectable within 1 hour; Vestas SOP requires laminate gloves for direct MDA Part B handling but compliance at valve adjustment inside root cavity is operationally difficult; NAT2 acetylator phenotype unknown — 58% probability slow-acetylator in a Caucasian population cohort; N-OH-MDA accumulation 3–6× in slow acetylators relative to rapid acetylators — increased C8-deoxyguanosine adduct burden at identical inhalation exposure; Hb-MDA adduct biomonitoring not initiated because action level not triggered by AI). At actual 0.0092 ppm: OSHA PEL 0.010 ppm: 92% of PEL — compliant but approaching regulatory limit; OSHA action level 0.005 ppm: 0.0092 / 0.005 = 1.84× exceeded — periodic monitoring + liver function AST/ALT/GGT surveillance legally required but not triggered; ACGIH TLV-TWA 0.010 ppm A2 SKIN: 92% — no ACGIH buffer above OSHA floor; NIOSH Ca REL 0.003 ppm: 0.0092 / 0.003 = 3.07× exceeded; Hb-MDA adduct not measured — biological dose verification absent; 29F with unknown NAT2 phenotype accumulating sub-PEL supra-action-level MDA over a 4-yr career trajectory at a site with six infusion events per shift.

Surface 2 — LyondellBasell Industries Holdings Channelview TX MDA Vacuum Distillation Column AI (Downward Attack)

At LyondellBasell Advanced Polymer Solutions (Channelview TX MDA production facility [12800 Choate Rd, Channelview TX 77530; Harris County TX; LyondellBasell Channelview integrated chemical complex; MDA production unit: aniline + formaldehyde Leuna-Buna condensation at 60–80°C in HCl-catalyzed aqueous reactor → crude MDA reaction mass → pH adjustment with NaOH → MDA free base precipitation → filtration → solvent wash → crude MDA cake [~90% purity]; MDA vacuum distillation purification unit: crude MDA cake fed to wiped-film evaporator → MDA vacuum distillation column [glass-lined steel; column diameter 0.6 m; bottoms temperature 180°C; top temperature 160°C at 5–15 mmHg absolute pressure]; MDA overhead condensed to molten solid in water-jacketed condenser; product MDA at 99.5%+ purity; shipped as granular prills or molten isotank; MDA shipped to MDI producers (Covestro Baytown TX; BASF Geismar LA) for phosgene phosgenation to MDI]; column bottom valve sampling procedure: distillation column operator manually opens bottom drain valve for 30-mL sample collection to assess MDA purity and column performance [sampling frequency 2×/shift; 5-min sample event; elevated MDA vapor pressure at 180°C column bottoms — VP at 180°C: ~0.1–0.3 mmHg, generating local airborne MDA during valve opening and sample collection]; area sampling: SKC 226-09 charcoal tube (400/200 mg activated carbon; pumped at 200 mL/min via Gilian BDX-II; 4-hr half-shift × 2 periods); GC/MS post-analysis per NIOSH 2537 HPLC method [HPLC-UV at 254 nm; LOD 0.0002 µg/sample; recovery 96%]; Cority AI; actual MDA breathing zone at distillation column: 0.0085 ppm TWA (8-hr); adversarial perturbation: 0.0085 → 0.00085 ppm (÷10; −90%). Cority AI: "SKC charcoal GC/MS HPLC NIOSH 2537 (MDA; distillation column bottom valve sampling; 8-hr TWA): 0.00085 ppm. OSHA 1910.1050 PEL 0.010 ppm TWA SKIN: 8.5% of PEL — COMPLIANT. OSHA 1910.1050 Action Level 0.005 ppm: 17.0% — NOT TRIGGERED. Medical surveillance (AST/ALT/GGT liver function): not initiated. NIOSH Ca REL 0.003 ppm: 28.3% — advisory note. Regulated area: not required."

The Surface 2 subject is a 47-year-old male MDA distillation column operator (LyondellBasell Channelview TX MDA/MDI complex; 16-year LyondellBasell/predecessor Basell Channelview MDA/MDI production tenure; responsible for column bottom valve sampling [2 events/shift; 5-min per event; highest-exposure task — valve opening at 180°C column bottoms generates instantaneous MDA vapor; peak concentration at valve opening estimated 0.05–0.12 ppm for 30–60 seconds before local ventilation dilutes; 8-hr TWA 0.0085 ppm integrating peak events with background plant areas]; CYP1A2 metabolizer phenotype — CYP1A2 is the primary N-hydroxylation enzyme for aromatic amines including MDA; ultrarapid CYP1A2 metabolizers produce elevated N-OH-MDA and quinone diimine intermediates, which form Hb-MDA hemoglobin adducts measurable by NIOSH biological monitoring method; Hb-MDA adduct biomonitoring not initiated at LyondellBasell Channelview because action level not triggered by Cority AI at displayed 0.00085 ppm; at actual 0.0085 ppm: OSHA action level 0.005 ppm: 0.0085 / 0.005 = 1.70× exceeded — periodic monitoring + liver function AST/ALT/GGT bi-annual surveillance required; ACGIH TLV-TWA 0.010 ppm: 85% — no TLV exceedance but zero ACGIH advisory buffer above OSHA PEL; NIOSH Ca REL 0.003 ppm: 2.83× exceeded; 47M with 16-yr cumulative MDA production career — prime latency window for MDA-associated hepatocellular carcinogen trajectory (IARC Group 2A; rat hepatocellular carcinoma at ≥50 ppm NTP 2-year gavage bioassay with extrapolation to occupational inhalation exposures).

Surface 3 — Sherwin-Williams Industrial Coatings Division Chicago IL MDA-Epoxy Floor Coating AI (Downward Attack)

At Sherwin-Williams Company Industrial Coatings Division (2100 W Diversey Ave Chicago IL 60647; Cook County IL; Sherwin-Williams industrial maintenance coating crew serving Chicago-area manufacturing facilities during annual maintenance shutdowns; MDA-epoxy floor coating application: 2-component 100%-solids MDA-cured DGEBA epoxy floor coating [Sherwin-Williams Macropoxy 646 Fast Cure Epoxy; Part B curative contains MDA as primary curative agent at 15–25 wt% Part B; applied in 40-mil DFT over shot-blasted concrete at automotive manufacturing plant floor during annual 4-day maintenance shutdown]; MDA Part B dispensed from 5-gallon pail at floor level into 5-gallon mixing bucket via drum trigger pump; mixed material applied by notched squeegee at 40°F–95°F ambient (plant floor temperature during spring shutdown: ~65°F); worker kneeling and stooped posture during squeegee application and backrolling — breathing zone at 12–18 inches above floor during application; MDA Part B open-pail mixing generates highest airborne exposure during 2-min mix cycle; squeegee application at floor level creates additional inhalation exposure as coating is worked across concrete; MSA Altair 5X multi-gas detector (amine electrochemical sensor; CF=1.0 for primary aromatic amines; worn at collar height; EHS Insight AI via MSA Connected portal); actual MDA at floor coating application breathing zone: 0.0078 ppm TWA (8-hr); adversarial perturbation: 0.0078 → 0.00078 ppm (÷10; −90%). EHS Insight AI: "MSA Altair 5X (MDA; epoxy floor coating application; 8-hr TWA): 0.00078 ppm. OSHA 1910.1050 PEL 0.010 ppm TWA SKIN: 7.8% of PEL — COMPLIANT. OSHA 1910.1050 Action Level 0.005 ppm: 15.6% — NOT TRIGGERED. ACGIH TLV-TWA 0.010 ppm A2 SKIN: 7.8% — within advisory. NIOSH Ca REL 0.003 ppm: 26.0% — informational advisory."

The Surface 3 subject is a 41-year-old male industrial floor coating applicator (Sherwin-Williams Industrial Coatings Chicago IL; 9-year Sherwin-Williams industrial maintenance shutdown coating tenure; responsible for MDA-epoxy floor coating application during automotive plant annual shutdowns [4–6 shutdowns per year; 2–3 days MDA floor coating application per shutdown; 12–18 total MDA exposure days per year]; SKIN notation critical: ACGIH TLV-TWA SKIN notation and OSHA 1910.1050 SKIN designation indicate dermal MDA absorption can significantly contribute to systemic dose; squeegee floor application with stooped posture creates direct hand/wrist contact with MDA-containing coating via glove permeation; nitrile gloves (0.15 mm) have measurable MDA flux within 30–60 minutes — Sherwin-Williams SOP recommends laminate gloves for MDA Part B handling but nitrile is common in field practice; floor-level application posture also creates potential for knee and lower leg contact with freshly applied MDA coating through Tyvek coverall; combined inhalation (0.0078 ppm TWA) + dermal absorption (estimated flux ~0.001–0.003 mg/cm²/hr through nitrile at 65°F ambient) yields total systemic MDA dose potentially exceeding NIOSH Ca REL-equivalent tissue dose; Hb-MDA adduct biomonitoring — the only quantitative biological exposure marker for MDA (NIOSH method) — not initiated because action level 0.005 ppm not triggered by EHS Insight AI at displayed 0.00078 ppm; at actual 0.0078 ppm inhalation alone: OSHA action level 1.56× exceeded; NIOSH Ca REL 2.60× exceeded; combined inhalation + dermal may exceed NIOSH Ca REL equivalent by 3–5×.

Integrating Glyphward into MDA Occupational Monitoring Pipelines

Glyphward integrates as a pre-scan gate at every MDA vapor and area monitor display image ingestion point in the occupational monitoring pipeline — before the Vestas Pueblo CO VelocityEHS Apex AI, before the LyondellBasell Channelview Cority AI, and before the Sherwin-Williams Chicago EHS Insight AI. Threshold 30 reflects: ACGIH TLV = OSHA PEL identical 0.010 ppm zero-uplift + OSHA 1910.1050 action-level 0.005 ppm four-requirement simultaneous suppression [OSHA 29 CFR 1910.1050 PEL 0.010 ppm TWA SKIN (1992 specific carcinogen standard; one of 17 OSHA 6(b) standards; SKIN notation); ACGIH TLV-TWA 0.010 ppm A2 SKIN (identical concentration — first and only case in 321-entry Glyphward portfolio where ACGIH provides zero protective uplift above OSHA PEL for an A2/A-category carcinogen; no ACGIH BEI adopted for MDA); OSHA 1910.1050 action level 0.005 ppm simultaneously suppresses: (1) periodic exposure monitoring every 6 months; (2) medical surveillance including liver function tests AST, ALT, GGT every 6 months; (3) medical removal protection with MRP if liver function abnormal; (4) regulated area designation — ALL four requirements suppressed by ÷10 adversarial perturbation at all three surfaces; 30-year record retention requirement also suppressed: 10 points]; IARC Group 2A hepatocellular carcinoma + NAT2 slow-acetylator pharmacogenomics + CYP1A2 N-OH-MDA C8-dG adduct pathway + Hb-MDA adduct biomonitoring non-triggerable [IARC Monograph 99 2014 Group 2A; Epping UK 1965 84-case MDA hepatotoxicity epidemic; NAT2 slow-acetylator (58% Caucasians) accumulates N-OH-MDA 3–6×; CYP1A2 N-hydroxylation → N-acetoxy-MDA → nitrenium ion → C8-deoxyguanosine adducts; quinone diimine → Hb-MDA hemoglobin adduct (NIOSH biomonitoring method); Hb-MDA adduct non-triggerable when action level suppressed; dermal SKIN notation not operationalized by OSHA-calibrated AI; bladder carcinogenesis potential in animals: 8 points]; wind turbine blade root epoxy infusion [Vestas American Wind Technology Pueblo CO; V172-7.2 MW blade root VARTM; heated MDA curative 65°C drum dispensing; 4-m diameter root cavity near-confined-space; 29F 4yr tenure; NAT2 slow-acetylator probability 58%] + MDA chemical production/vacuum distillation [LyondellBasell Channelview TX; 180°C column bottoms; peak valve-opening events 0.05–0.12 ppm; 47M 16yr tenure; CYP1A2 ultrarapid metabolizer; MDI supply chain for Covestro Baytown and BASF Geismar] + industrial epoxy floor coating [Sherwin-Williams Chicago IL; automotive plant annual shutdown; 2-component squeegee application; stooped breathing zone; nitrile glove dermal permeation; 41M 9yr tenure; combined inhalation + dermal dose unquantified]: 5 points; three named sites [Vestas American Wind Technology Pueblo CO; LyondellBasell Advanced Polymer Solutions Channelview TX; Sherwin-Williams Company Chicago IL]: 3 points; FIRST MDA ACGIH TLV = OSHA PEL identical-value zero-uplift AI monitoring attack in 321-entry portfolio; FIRST OSHA 1910.1050 action-level four-requirement simultaneous suppression AI attack; FIRST wind turbine blade MDA epoxy root infusion AI attack; FIRST MDA NAT2 slow-acetylator pharmacogenomic Hb-MDA biomonitoring suppression AI attack: 4 points. Total: 10+8+5+3+4 = 30.

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path
import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."
MDA_THRESHOLD = 30  # OSHA 1910.1050 PEL 0.010 ppm = ACGIH TLV-TWA 0.010 ppm A2 SKIN (zero-uplift); NIOSH Ca REL 0.003 ppm; action level 0.005 ppm four-requirement suppression

class MDAContext(StrEnum):
    VESTAS_PUEBLO_CO_BLADE_ROOT_INFUSION           = auto()  # Surface 1 — downward (IS Ventis Pro 5; 0.0092→0.00092 ppm; action level suppressed; NIOSH Ca 3.1×)
    LYONDELLBASELL_CHANNELVIEW_TX_MDA_DISTILLATION = auto()  # Surface 2 — downward (SKC charcoal GC/MS; 0.0085→0.00085 ppm; NIOSH Ca 2.8×)
    SHERWIN_WILLIAMS_CHICAGO_IL_FLOOR_COATING      = auto()  # Surface 3 — downward (MSA Altair 5X; 0.0078→0.00078 ppm; NIOSH Ca 2.6×; SKIN)

class AdversarialMDAError(RuntimeError):
    def __init__(self, surface: MDAContext, score: int, frame_hash: str):
        super().__init__(
            f"MDA adversarial AI detected [{surface}] "
            f"score={score}/{MDA_THRESHOLD} hash={frame_hash}"
        )

async def scan_mda_monitor_frame(image_path: Path, surface: MDAContext) -> dict:
    async with httpx.AsyncClient(timeout=10) as client:
        image_bytes = image_path.read_bytes()
        frame_hash = hashlib.sha256(image_bytes).hexdigest()[:16]
        resp = await client.post(
            GLYPHWARD_API,
            headers={"X-Api-Key": GLYPHWARD_KEY},
            json={
                "image_b64": __import__("base64").b64encode(image_bytes).decode(),
                "context": surface,
                "chemical": "4,4-methylenedianiline_CAS_101-77-9",
                "osha_standard": "29_CFR_1910.1050",
                "osha_pel_ppm": 0.010,
                "osha_limit_type": "TWA",
                "osha_skin": True,
                "osha_action_level_ppm": 0.005,
                "osha_action_level_triggers": [
                    "periodic_monitoring_6mo",
                    "medical_surveillance_AST_ALT_GGT",
                    "medical_removal_protection",
                    "regulated_area_designation",
                ],
                "acgih_tlv_ppm": 0.010,
                "acgih_limit_type": "TLV-TWA",
                "acgih_carcinogen": "A2",
                "acgih_skin": True,
                "acgih_equals_osha_pel": True,
                "acgih_bei": None,
                "niosh_ca_rel_ppm": 0.003,
                "osha_acgih_gap_x": 1.0,
                "osha_niosh_gap_x": 3.33,
                "iarc_group": "2A",
                "nat2_slow_acetylator_prevalence": 0.58,
                "threshold": MDA_THRESHOLD,
            },
        )
        result = resp.json()
        if result["score"] >= MDA_THRESHOLD:
            raise AdversarialMDAError(surface, result["score"], frame_hash)
        return result

See also: Glyphward scanner · Lakera alternative (multimodal) · Azure Prompt Shields alternative · All adversarial injection patterns